An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period (NEO)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01112657
First received: March 10, 2010
Last updated: July 9, 2014
Last verified: July 2014
  Purpose

This is a prospective, multicentric, observational study with a 2 years recruitment period. The purpose of the study is to observe the multiple sclerosis (MS) progression of subjects since their first episode of neurological event and secondly, to determine status of anti-AQP4 immunoglobulin (IgG) antibody in MS subjects.


Condition
Multiple Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Observational Study On The Progression Of Clinically Isolated Syndrome (CIS) To Multiple Sclerosis Over A 2-year Period

Resource links provided by NLM:


Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Proportion of subjects who convert to multiple sclerosis (MS), defined by McDonald criteria (Version 2005), over 2 years from the first episode of Clinically Isolated Syndrome (CIS) [ Time Frame: Baseline to 2 years ] [ Designated as safety issue: No ]
    At each and every visit, routine neurological and or ophthalmologic examinations will be performed to determine whether subject has progress to MS.


Secondary Outcome Measures:
  • Duration between first episode of neurological event and diagnosis of MS [ Time Frame: Baseline to 2 years ] [ Designated as safety issue: No ]
  • Proportion of subjects with conventional MS and optic-spinal MS (OSMS) [ Time Frame: Baseline to 2 years ] [ Designated as safety issue: No ]
  • Proportion of subjects with anti-AQP4 IgG antibody [ Time Frame: Baseline to 2 years ] [ Designated as safety issue: No ]
    Blood samples shall be taken at baseline, 12-16 weeks after baseline and end of study (for subjects who converted to MS) for anti-AQP4 IgG antibody measurements

  • Association between baseline demographics/disease characteristics and progression to MS [ Time Frame: Baseline to 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Whole blood


Enrollment: 254
Study Start Date: November 2008
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Multiple sclerosis is chronic, inflammatory disease of the central nervous system (CNS) characterised by areas of demyelination, or plaques, in the CNS. In 85% of subjects who later develop MS, clinical onset is with an acute or subacute episode of neurological disturbance due to a single white-matter lesion (e.g. optic neuritis, or an isolated brainstem or partial spinal-cord syndrome). This presentation is known as a Clinically Isolated Syndrome (CIS). Because a CIS is typically the earliest clinical expression of MS, research on subjects with a CIS may provide new insights into early pathological changes and pathogenetic mechanisms that might affect the course of the disorder.

In the group of subjects with optic-spinal MS (OSMS), the main lesions are typically confined to the optic nerve and spinal cord. In Asians, OSMS has similar features to the relapsing remitting form of neuromyelitis optica (NMO) seen in Westerners. It is still a matter of debate whether NMO represents a disease entity in itself or whether it is a subform of MS. Early differentiation of NMO from MS is highly desirable, as treatment options and prognoses differ widely. Recently, a new serum autoantibody (NMO-IgG) has been detected in NMO subjects. The binding sites of this autoantibody were reported to colocalize with aquaporin 4 (AQP4) water channels. Optic-spinal MS is sometime suggested to be NMO based on the frequent detection of the anti-AQP4 IgG antibody. In Taiwan, study has shown that 56% of MS subjects were of the optic-spinal type.

OBJECTIVES

The study is designed firstly, to observe the MS progression of subjects since their first episode of neurological event and secondly, to determine status of anti-AQP4 IgG antibody in MS subjects.

Primary objective:

  • To describe the progression of subjects who have experienced a CIS to MS over a 2-year period

Secondary objectives:

  • To assess the relationship between CIS and MS including optic-spinal MS (OSMS)
  • To determine the status of anti-AQP4 IgG antibody in subjects who convert to MS

Each subject shall be followed up for 2 years after enrolment. At baseline, routine examinations shall be performed to confirm subject's neurological episode. After the baseline visit, the subject shall be instructed to return for further examination if he/she experiences a relapse. During the follow-up examinations, the treating physician shall determine whether the subject fulfil the diagnostic criteria for MS.

If subject is being diagnosed with MS, he/she shall be considered as reaching the end of his/her study participation. Further management of the MS condition will be at the discretion of the treating physician. During 2-year follow-up period, telephone calls to the subject shall be made quarterly to assess subject's neurological and/or visual status and to remind subject that he/she need to return for evaluation in the event of a relapse. All data will be collected using a standardised case report form (CRF).

  Eligibility

Ages Eligible for Study:   6 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects who have experienced a single, first clinical event potentially suggestive of MS within the last 2 years from study entry.

Criteria

Inclusion Criteria:

  • Subjects aged between 6-60 years, both inclusive
  • Subjects who have experienced a single, first clinical event potentially suggestive of MS within the last 2 years from study entry. The event must be a new neurological abnormality present for at least 24 hours, either mono- or polysymptomatic, other than paresthesia or vegetative dysfunction
  • Subjects who have given written informed consent.

Exclusion Criteria:

  • Subjects with the diagnosis of MS
  • Subjects with other disease that could better explain the subject's signs and symptoms
  • Subjects who are scheduled to participate in any interventional treatment trial
  • Subjects who have any condition that could interfere with MRI evaluation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01112657

Locations
Taiwan
Kaohsiung Medical University, Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
Chang-Gung Memorial Hospital - Kaohsiung Branch
Kaohsiung, Taiwan, 833
China Medical University Hospital
Taichung, Taiwan, 404
National Taiwan University Hospital
Taipei, Taiwan, 100
Taipei Veterans General Hospital
Taipei, Taiwan, 201
Chang-Gung Memorial Hospital - Linkou Branch
Taoyuan, Taiwan, 333
Sponsors and Collaborators
Merck KGaA
Investigators
Principal Investigator: Ching-Piao Tsai, MD Taipei Veterans General Hospital, Taiwan
  More Information

No publications provided

Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT01112657     History of Changes
Other Study ID Numbers: EMR200077-504
Study First Received: March 10, 2010
Last Updated: July 9, 2014
Health Authority: Taiwan: Department of Health

Keywords provided by Merck KGaA:
Multiple Sclerosis
Clinical isolated syndrome
Demyelination

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Syndrome
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Disease

ClinicalTrials.gov processed this record on September 16, 2014